Cryptococcus neoformas infection of the central nervous system (CNS) continues to be an important cause of mortality and morbidity, and a major contributing factor is our incomplete knowledge of the pathogenesis of this disease. Here, we provide the first direct evidence that C. neoformans exploits host cysteinyl leukotrienes (LTs), formed via LT biosynthetic pathways involving cytosolic phospholipase A 2 α (cPLA 2 α) and 5-lipoxygenase (5-LO) and acting via cysteinyl leukotriene type 1 receptor (CysLT1), for penetration of the blood-brain barrier. Gene deletion of cPLA 2 α and 5-LO and pharmacological inhibition of cPLA 2 α, 5-LO and CysLT1 were effective in preventing C. neoformans penetration of the blood-brain barrier in vitro and in vivo. 
| INTRODUCTION
Cryptococcus neoformans is responsible for life-threatening central nervous system (CNS) infection in immunocompromised patients, especially those infected with HIV-1 (Day et al., 2013; Eisenman, Casadevall, & McClelland, 2007; Hakim et al., 2000; Jarvis et al., 2009; Mitchell & Perfect, 1995; Mwaba et al., 2001; Park et al., 2009; Perfect & Casadevall, 2002; Powderly, 1993; Saag et al., 2000; Warkentien & Crum-Cianflone, 2010) . One million cases of cryptococcal meningoencephalitis are estimated to occur globally per year, with > 60% mortality within 3 months of infection (Day et al., 2013; Mwaba et al., 2001; Park et al., 2009) . Even when treatment with amphotericin B and flucytosine is available, mortality ranges between 15% and 30% and is much higher (41-70%) in low-income countries where such antifungal regimens are not readily accessible (Day et al., 2013; Jarvis et al., 2009; Mwaba et al., 2001; Park et al., 2009; Saag et al., 2000) . A recent study reported that cerebrospinal fluid (CSF) fungal burden predicts acute mortality in HIV-associated cryptococcal meningoencephalitis (Jarvis et al., 2009) . These findings illustrate the need for a novel strategy for decreasing fungal burden in improving outcomes in HIV-infected patients.
Cryptococcus neoformans CNS infection is a leading contributor to mortality in HIV-infected individuals with CD4+ counts < 100 cells μl −1 , the threshold at risk for cryptococcal CNS infection, and blood cryptococcal antigen (CRAG) screen and early institution of pre-emptive antifungal therapy is shown to be efficacious in improving survival (Boulware et al., 2014; Jarvis et al., 2009; Meya et al., 2010) . A 6 month survival in asymptomatic CRAG+ persons with CD4 < 100 μl −1 , however, is approximately 75% with the currently recommended WHO therapy, fluconazole (Boulware et al., 2014; Jarvis et al., 2009; Meya et al., 2010) . The timing of mortality, occurring several weeks later, suggests that better antifungal therapy may be able to improve outcomes. These findings indicate that new approaches are needed to investigate the pathogenesis, prevention and therapy of C. neoformans CNS infection. Development of such a strategy, however, has been hampered by our incomplete knowledge on how C. neoformans penetrates the blood-brain barrier (Kim, 2008) , the essential step required for the development of CNS infection.
Cryptococcus neoformans is commonly acquired by inhalation. & Perfect, 1995; Mwaba et al., 2001; Park et al., 2009; Perfect & Casadevall, 2002; Powderly, 1993; Saag et al., 2000; Warkentien & Crum-Cianflone, 2010) . Several lines of evidence from human cases and experimental animal models of C. neoformans meningoencephalitis indicate that C. neoformans penetration into the brain follows fungemia, and cerebral capillaries are the portal of entry into the brain (Chang et al., 2004; Charlier et al., 2005; Chrétien et al., 2002; Lee, Dickson, & Casadevall, 1996; Olszewski et al., 2004; Shi et al., 2010) . Since the entry of C. neoformans into the brain occurred in the cerebral microvasculature, we developed an in vitro blood-brain barrier model with human brain microvascular endothelial cells (HBMEC) (Chang et al., 2004; Kim, 2008; Kim, Di Cello, Hillaire, & Kim, 2004; Maruvada et al., 2012; Rüffer, Strey, Janning, Kim, & Gerke, 2004; Stins, Gilles, & Kim, 1997) for investigating C. neoformans penetration of the blood-brain barrier.
Cryptococcus neoformans penetration into the brain has been shown to involve mainly transcellular and Trojan-horse penetrations of the blood-brain barrier and has been examined in animal models of intravenous, intranasal and intratracheal inoculations (Chang et al., 2004; Charlier et al., 2005; Chrétien et al., 2002; Dromer & Levitz, 2011; Kim, 2008; Neuville et al., 2002; Olszewski et al., 2004; Shi et al., 2010) . Transcellular and Trojan-horse penetrations may not be mutually exclusive and can function in parallel in these animal models (Dromer & Levitz, 2011) . We showed that C. neoformans strains exhibit the ability to traverse the HBMEC monolayer without affecting HBMEC integrity, and HBMEC traversal is correlated with C. neoformans penetration into the brain (Chang et al., 2004; Kim, 2008; Maruvada et al., 2012; Shi et al., 2010) . The underlying mechanisms involved in C. neoformans penetration of the blood-brain barrier, however, remain incompletely understood.
Previous studies have identified several cryptococcal and host factors contributing to penetration into the brain, which include a cryptococcal metalloprotease as well as cps1-CD44 and plb1-Rac1 interactions (Vu et al., 2014; Chang, Jong, Huang, Zerfas, & KwonChung, 2006; Jong et al., 2012; Maruvada et al., 2012) . We identified the CysLT1 antagonist, montelukast from our chemical screen inhibiting C. neoformans traversal of HBMEC monolayer. CysLT1 has been previously shown to contribute to invasion of HBMEC monolayer and penetration into the brain by bacteria causing meningitis such as Escherichia coli and group B Streptococcus (Zhu et al., 2010; Maruvada et al., 2011) . Here, we elucidated the mechanisms by which cysteinyl leukotrienes are generated and contribute to C. neoformans penetration of the blood-brain barrier in vitro and in vivo.
| RESULTS AND DISCUSSION
Since C. neoformans traversal of the HBMEC monolayer is correlated with penetration into the brain, we used C. neoformans traversal of HBMEC monolayer as a relevant biological assay to screen a chemical library for discovery of targets affecting C. neoformans traversal of the blood-brain barrier. Our chemical screen identified montelukast as an inhibitor of C. neoformans traversal of HBMEC monolayer, yet montelukast did not affect the growth of C. neoformans strains B-3501A and H99 and also did not affect the HBMEC viability, as assessed by live/dead stain (Molecular probes) (Stins, Badger, & Kim, 2001 ). Montelukast is a selective antagonist of cysteinyl leukotriene type 1 receptor (CysLT1) and inhibits cysteinyl leukotriene (CysLT) binding to CysLT1 (Peters-Golden & Henderson, 2007) . Since host CysLTs are formed via LT biosynthetic pathways involving cytosolic phospholipase A 2 α (cPLA 2 α) and 5-lipoxygenase (5-LO), we hypothesise that host cPLA 2 α and 5-LO contribute to C. neoformans penetration of the blood-brain barrier.
We showed that C. neoformans strains exploit host cPLA 2 α for their traversal of HBMEC monolayer, as shown by the time-dependent cPLA 2 α phosphorylation in response to C. neoformans strains B-3501A and H99 (Fig. 1A ) and the ability of arachidonoyl trifluoromethylketone (AACOCF3, cPLA 2 α inhibitor) at 20 μM to significantly inhibit C. neoformans traversal of HBMEC monolayer (Fig. 1B ). were removed, weighed, homogenised and cultured for determinations of CFUs, as described previously (Chang et al., 2004; Maruvada et al., 2012) . C. neoformans strain B-3501A was completely cleared from the blood at 24 h after intravenous injection, and no viable yeasts were recovered from the blood. The CFUs in the brains were, therefore, most likely to represent the yeast cells that had penetrated into and survived in the brain.
For pharmacological inhibition, AACOCF3 (4 mM in 50 μl PBS, a dose which inhibits cPLA 2 α activity in mice; Kalyvas & David, 2004) was administered intravenously 30 min before C. neoformans injection, and this resulted in significantly decreased penetration of C. neoformans into the brain of BALB/c mice (Fig. 1E ). In contrast, AACOCF3 did not affect C. neoformans penetration into the spleen, kidney and lung, as shown by similar numbers of CFUs recovered from the animals receiving AACOCF3 or vehicle control (Fig. 1E ). Our previous studies revealed that traversal of C. neoformans across the HBMEC monolayer was evident over a 9 h incubation period (Chang et al., 2004) . At 9 h of incubation at 37°C, sample was taken from the lower chamber and plated for determinations of CFUs. Colonies were counted after 2 days of incubation at 30°C. Transcytosis frequency (%) was determined by (total CFUs recovered from the lower chamber/total number of cryptococcal cells added to the upper chamber) × 100 and expressed as relative frequency compared with transcytosis frequency with vehicle control (0.125% ethanol). Transcytosis frequency of C. neoformans strain B-3501A across HBMEC monolayer at 9 h of incubation at 37°C ranged between 1.4 and 8.9%. Data shown are means ± SEM of triplicates. *P < 0.05, unpaired t-test, compared with vehicle control. Pretreatment of HBMEC with montelukast significantly inhibited C.
neoformans traversal in a dose-dependent manner ( Fig. 3A and B) , while CP105696 did not exhibit any inhibition (Fig. 3C ). Montelukast at 50 μM did not affect the growth of C. neoformans strains and also did not affect the integrity of HBMEC monolayer, as assessed by TEER before and after traversal assays.
We next examined the effect of montelukast in C. neoformans penetration into the brain following intravenous inoculation. Administration of montelukast (1.6 mM in 100 μl PBS, a dose which exhibits CysLT1 antagonist activity in mice; Genovese et al., 2008) intravenously 15 min before and 6 h after C. neoformans injection significantly decreased C. neoformans penetration of the brain of BALB/c mice but did not affect C. neoformans penetration into the spleen, kidney and lung (Fig. 3D) . These in vitro and in vivo findings with montelukast demonstrate for the first time that cysteinyl LTs contribute to C. neoformans penetration of the blood-brain barrier.
Cysteinyl leukotriene type 1 receptor antagonists have been developed for allergic airway disease and shown to be safe and well tolerated in clinical trials (Barnes, de Jong, & Miyamoto, 1997; Capra et al., 2007; Montuschi, Sala, Dahlén, & Folco, 2007) . Since CysLT1 antagonist (montelukast) was effective in preventing C. neoformans penetration of the blood-brain barrier, we next examined its efficacy in the treatment of C. neoformans CNS infection, alone and in combination with anti-fungal drug (fluconazole). The animals received C. neoformans via intratracheal inoculation and then montelukast via intraperitonal administration, followed by daily administration of montelukast and fluconazole, alone or in combination, for 6 and 13 days to mimic a likely application of these drugs for therapy of C.
neoformans CNS infection. As expected, administration of fluconazole was effective in significantly inhibiting C. neoformans CFUs recovered from the brain compared with vehicle control (Fig. 3E and F) . The combination of montelukast and fluconazole, however, was significantly more effective than individual drugs alone in reducing C. neoformans
CFUs recovered from the brain (Fig. 3E and F ).
In addition, our immunofluorescence studies revealed that the expression of CysLT1 was evident in the brain capillaries of animals with C. neoformans penetration into the brain following intratracheal inoculation, while CysLT1 expression was not discernible in the brain capillaries of uninfected animals (Fig. 4) , suggesting that the CysLT1 expression in the brain capillaries is likely to be up-regulated with C. neoformans infection of the brain.
Taken together, these findings suggest that counteracting a host factor involved in C. neoformans penetration of the blood-brain barrier (e.g. cysteinyl LTs) is beneficial in prevention and therapy of C. neoformans CNS infection and also suggest that a combination of montelukast and fluconazole may represent an attractive preemptive therapeutic regimen for asymptomatic CRAG+ persons with CD4 < 100 μl
It has been documented that eicosanoids can be produced not only by the host but also by Cryptococcus phospholipase (Noverr, Cox, Perfect, & Huffnagle, 2003; Noverr, Phare, Toews, Coffey, & Huffnagle, 2001 ). We next examined whether prevention of C. neoformans penetration into the brain by the cPLA 2 α inhibitor and the CysLT1 antagonist was the result of their inhibitory effects on cysteinyl LTs arising from arachidonate liberated by Cryptococcus or host phospholipase. This issue was examined by using the phospholipase B1 (plb1) mutant derived from C. neoformans strain H99 compared with its reconstituted strain along with wild type strain H99 (Noverr et al., 2003) . As shown previously (Maruvada et al., 2012) , the penetration of the plb1 mutant across the HBMEC monolayer was significantly decreased compared with that of the reconstituted strain and strain H99 (Fig. 5A ). AACOCF3 and montelukast were effective in significant inhibition of HBMEC traversal by the plb1 mutant, the reconstituted and wild type strains (Fig. 5A ). More importantly, the penetration of the plb1 mutant into the brain was significantly defective in cPLA 2 α −/− mice compared with wild type mice (Fig. 5B ).
In contrast, the yeast counts recovered from non-brain sites (kidney, spleen and lung) did not differ between cPLA 2 α −/− and wild type mice.
We also showed that montelukast significantly inhibited the plb1 mutant's penetration into the brain compared with vehicle control (Fig. 5C ). Our findings with pharmacological inhibition of cPLA 2 α and CysLT1 as well as genetic deletion of cPLA 2 α are, therefore, likely to stem from their effect on host cPLA 2 α and CysLT1, not on fungal plb1, supporting that host cPLA 2 α and cysteinyl LTs contribute to C.
neoformans traversal of HBMEC and penetration into the brain, independent of Cryptococcus phospholipase. These findings are also consistent with those of pharmacological inhibition studies (Fig. 3D , E and F), where C. neoformans penetration into the brain was prevented by administration of montelukast alone and in combination with fluconazole, indicating that host-derived, rather than cryptococcal-derived, eicosanoid production is responsible for C. neoformans penetration of the blood-brain barrier. In addition, we showed that C. gattii strains exhibited the ability to traverse the HBMEC monolayer, and their traversal frequency (1.3% to 2.4%) was similar to that of C. neoformans.
Of interest, C. gattii traversal was inhibited by AACOCF3 and montelukast (Fig. 5D ). Taken PKCα activation occurs in response to C. neoformans in a time-dependent manner in HBMEC (Fig. 6A ) and that C. neoformans traversal was significantly decreased in HBMEC expressing dominant-negative
PKCα compared with the control vector-transfected HBMEC (Fig. 6B and C). for each group). Data shown are mean ± SEM. *P < 0.05 by two-tailed Wilcoxon Rank-Sum test. (e and f) Effects of montelukast and fluoconzole on C. neoformans penetration into the brain of BALB/c mice (e) 7 and (f) 14 days after intratracheal inoculation of H99. On the day of intratracheal inoculation of C. neoformans, montelukast (Mon) was given at dose of 5 mg kg −1 in 100 μl PBS via intraperitoneal (i.p.) injection 30 min before and 6 h after inoculation of H99, followed by 5 mg kg −1 i.p. daily for 6 and 13 days. After intratracheal inoculation of C. neoformans, fluconazole (Flu) was suspended in sterile water and was given at dose of 15 mg kg −1 twice daily in a volume about 100 μl by gavage for 6 and 13 days. Control animals received 3.3% DMSO i.p. and sterile water via oral gavage. The yeast counts from the brain were determined 7 and 14 days after intratracheal inoculation of H99 (1 × 10 5 CFUs). Data represent mean ± SEM (n = 10). *P < 0.05 by Student's t-test.
More importantly, PKCα activation in response to C. neoformans was inhibited by cPLA 2 α inhibitor (AACOCF3) and CysLT1 antagonist (montelukast), but not by BLT1 antagonist (CP105696) (Fig. 6A ). These to exhibit such an enhancement in HBMEC expressing dominantnegative PKCα (Fig. 6B and C) . In addition, PKCα activation was shown to occur in response to LTD4, but not to LTB4, in HBMEC (Fig. 6D ).
Taken together, these findings demonstrate for the first time that Yellow arrows indicate H99-GFP, and white arrows indicate microvessels. Scale bar = 50 μm.
FIGURE 5 Roles of cryptococccal plb1 in C. neoformans penetration of the blood-brain barrier. (a). The plb1 mutant (ΔPLB1) was significantly defective in traversal of the HBMEC monolayer compared with its parent strain H99 and reconstituted strain (ΔPLB1 + R). AACOCF3, a cPLA2α inhibitor, and montelukast, the CysLT1 antagonist, significantly inhibited the HBMEC traversal of the plb1 mutant, its parent strain and reconstituted strain. Traversal of the HBMEC monolayer was examined in Transwell filters (8 μm pore size). HBMEC were pretreated with 20 μM AACOCF3 for 60 min, and then 20 μM AACOCF3 fresh solution were added to the transwell every 2 h (0, 2, 4, 6 and 8 h respectively), or HBMECs were pretreated with 50 μM montelukast for 60 min, and then montelukast solution were added every 4 h (0, 4 and 8 h respectively) after addition of 1 × 10 6 CFUs of cryptococcal strains to the upper chamber. Data shown are means ± SEM of triplicates. *P < 0. 
| Yeast strains
Cryptococcus neoformans strains H99 and B-3501A represent encapsulated serotype A and D strains, respectively, that have been used for genomic sequencing (Loftus et al., 2005) . plb1 isogenic strain of H99 was generated as previously described (Cox et al., 2001) . GFP-tagged H99 (H99-GFP) was provided by Robin C. May, University of Birmingham, UK (Voelz, Johnston, Rutherford, & May, 2010) . C. gattii strains were provided by S. Zhang, Johns Hopkins Hopsital Microbiology Laboratory.
Yeast cells were grown aerobically at 37°C in 1% yeast extract, 2% Transwell inserts (with a pore size of 8 μm) were incubated with the JHDL (at a final concentration of 10 μM) for 60 min at room temperature and then examined for C. neoformans traversal, as previously described (Chang et al., 2004; Maruvada et al., 2012) . This screening assay included strain H99 in vehicle (DMSO)-treated HBMEC as a positive control for transcytosis, while the wells without HBMEC were used as control for any inhibitory effect of the drugs on growth of C.
neoformans. Since this JHDL contains antifungal drugs, those wells exposed to antifungals were used as a positive control for determination of drugs that affect C. neoformans growth. The assay was highly reproducible, and the coefficient of correlation from at least two separate experiments was r = 0.98 (P < 0.0001). From this screen, we CaCl2, 1.2 MgSO4, 5.5 glucose, 5.0 NaHCO3 and 20 HEPES and Na-HEPES, containing 10 mg ml −1 BSA; pH of the Ringer solution was maintained at 7.40-7.45 by adjustment of the ratio of Na-HEPES to HEPES. Ringer solution used in this study has been shown not to change the microvessel permeability (Zhu, Schwegler-Berry, Castranova, & He, 2004) . Thirty minutes after perfusion of Ringer solution, mice were decapitated. The brains were removed, weighed and homogenised in 2 ml RPMI followed by plating for brain Cryptococcus counts in YPD agar plates. Kidneys, lungs and spleens were also dissected out for determinations of bacterial counts (CFUs gm −1
). The brains were removed, weighed and homogenised in 2 ml RPMI followed by plating for brain Cryptococcus counts in YPD agar plates.
| Intratracheal inoculation
Mice were anaesthetised with pentobarbital sodium given subcutaneously at 50 mg kg Slides were imaged through fluorescence microscopy with a Nikon Eclipse Ti-S and DS-Ri2 digital camera (Nikon).
| Immunoblotting and immunoprecipitation
The lysates of HBMEC incubated with C. neoformans were prepared for Western blotting and immunoprecipitation as described previously (Reddy, Prasadarao, Wass, & Kim, 2000) . 
| Statistical Analysis

